ES2550754T3 - Proteína matriptasa y usos de la misma - Google Patents

Proteína matriptasa y usos de la misma Download PDF

Info

Publication number
ES2550754T3
ES2550754T3 ES08795130.7T ES08795130T ES2550754T3 ES 2550754 T3 ES2550754 T3 ES 2550754T3 ES 08795130 T ES08795130 T ES 08795130T ES 2550754 T3 ES2550754 T3 ES 2550754T3
Authority
ES
Spain
Prior art keywords
cancer
antibody
matriptase
stem
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08795130.7T
Other languages
English (en)
Spanish (es)
Inventor
Christian Rohlff
Jonathan Alexander Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biotherapeutics Ltd
ER Squibb and Sons LLC
Original Assignee
Oxford Biotherapeutics Ltd
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biotherapeutics Ltd, ER Squibb and Sons LLC filed Critical Oxford Biotherapeutics Ltd
Application granted granted Critical
Publication of ES2550754T3 publication Critical patent/ES2550754T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES08795130.7T 2007-08-07 2008-08-07 Proteína matriptasa y usos de la misma Active ES2550754T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96383707P 2007-08-07 2007-08-07
US963837P 2007-08-07
PCT/US2008/009512 WO2009020645A2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof

Publications (1)

Publication Number Publication Date
ES2550754T3 true ES2550754T3 (es) 2015-11-12

Family

ID=40239716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08795130.7T Active ES2550754T3 (es) 2007-08-07 2008-08-07 Proteína matriptasa y usos de la misma

Country Status (7)

Country Link
US (1) US8420091B2 (enExample)
EP (1) EP2185933B1 (enExample)
JP (2) JP5864856B2 (enExample)
AU (1) AU2008284271B2 (enExample)
DK (1) DK2185933T3 (enExample)
ES (1) ES2550754T3 (enExample)
WO (1) WO2009020645A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US20120294800A1 (en) * 2009-01-07 2012-11-22 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US8420084B2 (en) * 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CA2887037A1 (en) 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activated matriptase
EA201690806A1 (ru) * 2013-11-25 2016-09-30 Оксфорд Байотерапьютикс Лтд. Антитела
KR102441107B1 (ko) * 2014-11-07 2022-09-13 후지쿠라 가세이 가부시키가이샤 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법
AU2017235571B2 (en) 2016-03-18 2024-05-16 Georgetown University Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022821B1 (en) * 1998-02-20 2006-04-04 O'brien Timothy J Antibody kit for the detection of TADG-15 protein
US5972616A (en) 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
JP4778617B2 (ja) 1999-03-12 2011-09-21 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
EP1226150A4 (en) * 1999-10-20 2005-05-25 Univ Arkansas TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA
US6447978B1 (en) 1999-12-03 2002-09-10 Kodak Polychrome Graphics Llc Imaging member containing heat switchable polymer and method of use
JP2003521920A (ja) 2000-02-03 2003-07-22 コルバス・インターナショナル・インコーポレイテッド 膜貫通セリンプロテアーゼをコードしている核酸分子、コードされたタンパク質、およびそれらに基づく方法
US6903201B2 (en) 2001-01-05 2005-06-07 Curagen Corporation Proteins and nucleic acids encoding same
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
KR20040080940A (ko) 2001-05-14 2004-09-20 덴드레온 코포레이션 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US8239547B2 (en) 2004-07-09 2012-08-07 Telefonaktiebolaget Lm Ericsson (Publ) Method and arrangement for providing different services in a multimedia communication system
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
AU2008284271B2 (en) 2014-03-13
DK2185933T3 (en) 2015-10-26
US20100285017A1 (en) 2010-11-11
AU2008284271A1 (en) 2009-02-12
JP2014223083A (ja) 2014-12-04
US8420091B2 (en) 2013-04-16
JP5864856B2 (ja) 2016-02-17
EP2185933B1 (en) 2015-10-07
WO2009020645A2 (en) 2009-02-12
WO2009020645A3 (en) 2009-05-07
JP2010535506A (ja) 2010-11-25
EP2185933A2 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
ES2745014T3 (es) Proteína
ES2813360T3 (es) Diana terapéutica y diagnóstica para el cáncer que comprende reactivos de unión a DLL3
ES2550754T3 (es) Proteína matriptasa y usos de la misma
US20120282177A1 (en) ROR1 as Therapeutic and Diagnostic Target
JP7079685B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
US20190310255A1 (en) Proteins
JP2011509079A (ja) エフリンａ型受容体１０タンパク質
ES2615256T3 (es) Objetivo terapéutico y de diagnóstico
US20110229480A1 (en) Pta072 protein
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
EP2447719A1 (en) Proteins
US20150210770A1 (en) Therapeutic and diagnostic target
US20120058131A1 (en) Pta089 protein